J

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Senior Oncology Account Manager

Full-TimeUpdated on 10/24/2026
$155.2k - $232.8k
Mid
Bachelor's
South Dakota, USA+1 moreMore locations: Omaha, NE, USA
RemoteRemote home-based territory covering Nebraska, South Dakota, and part of Iowa; frequent travel between meeting sites.
Sales & Account ManagementField Sales

About the job

Requirements
  • Possess a four-year college or university degree.
  • Have experience in oncology.
  • Have excellent verbal and written communication skills and an effective presentation style for face-to-face and virtual interactions with healthcare professionals.
  • Be able to meet territorial travel requirements.
  • Possess strong sales analytics capabilities and understand prescribing and purchasing decision processes and differences from national trends.
  • Understand internal customer business models, including profit generation, business and financial risks, and costs of managing patient care.
  • Understand external customer reimbursement landscapes, managed care, payer issues and trends, and other factors that inform annual territory business plans.
  • Research and analyze customer needs and requirements for each customer or account.
  • Identify key account stakeholders and understand their roles, priorities, motivations, and patient needs.
  • Leverage dashboards, alerts, omnichannel reports, speaker programs, and conference attendance.
  • Gain customer insights and provide timely feedback to cross-functional partners and the regional sales manager regarding account trends, therapeutic landscape changes, performance, industry issues, business opportunities, and obstacles.
  • Define clear, measurable objectives aligned with company goals and customer needs.
  • Develop tailored strategies and tactics for each customer’s needs and challenges and determine the resources required to execute account plans.
  • Review and adjust strategic account plans based on activities, feedback, market conditions, and evolving customer needs.
  • Collaborate with cross-functional teams, including marketing, medical affairs, and market access, to align account strategies and business objectives.
  • Identify patterns and trends from multichannel data for collaborative problem solving.
  • Maintain an enterprise mindset and cross-functional approach to customer engagement.
  • Promote Jazz Pharmaceuticals adult oncology products to physicians and other healthcare providers in community and academic centers.
  • Stay abreast of oncology industry trends, competitive landscape, and clinical developments to communicate product differentiation and value.
  • Adapt to new tools and resources for customer engagement and use analytics to develop insights and next-best-action plans.
  • Establish and maintain relationships with physicians, healthcare providers, and organizations in the assigned territory.
  • Educate physicians and healthcare professionals about company products and approved indications in small cell lung cancer and gastrointestinal cancers.
  • Answer customer questions about approved products and therapies using package-insert clinical information and company compliance guidelines.
  • Maintain clinical knowledge of disease states and Jazz products based on package-insert information.
  • Organize and facilitate meetings for medical and product information exchanges in accordance with company policies and regulatory and legal requirements.
  • Represent the company at live and virtual conferences, company meetings, educational events, training programs, and other functions as needed.
  • Use customer relationship management tools to manage customer interactions, track sales activities, and maintain accurate territory records.
  • Follow ethical pharmaceutical marketing policies and procedures and applicable legal and regulatory guidelines, including the Food, Drug and Cosmetic Act, Prescription Drug Marketing Act, Pharma Code, OIG guidelines, and other applicable federal and state regulations.
  • Perform activities within the allocated budget.
  • Travel frequently between meeting sites and interact frequently with external contacts in their office environments.
  • Operate computers, printers, telephones, and similar office machinery; frequently use a laptop or tablet away from a workstation.
  • Work outside normal business hours when needed to meet business demands.
  • Maintain appropriate business apparel for frequent public contact.
Responsibilities
  • Promote Jazz Pharmaceuticals products directly and develop and manage business relationships with therapeutic specialists in the assigned geographical territory.
  • Implement Jazz Pharmaceuticals’ marketing strategies and tactics to achieve sales goals through short-term and long-term objectives.
  • Develop and implement customized strategic account plans with clear next steps, strategies, tactics, and appropriate resource use.
  • Work with customer-facing colleagues to facilitate achievement of their functional tactical objectives.
  • Modify call-plan and business-plan activities and develop alternate plans when the work environment changes.
  • Share insights and best practices across the team and contribute to cross-functional partners’ effectiveness and impact.
  • Lead as the main point of contact for designated accounts when appropriate and coordinate a streamlined interface between account stakeholders and field-facing colleagues.
  • Use a network-selling approach to broaden connections across healthcare accounts.
  • Appropriately challenge prescribers about treatment decisions associated with assigned products.
  • Complete special projects as assigned.
Desired Qualifications
  • Post-graduate business school study or training.
  • A minimum of five years in the oncology market.
  • Strong clinical, technical, and scientific knowledge of products and applicable disease states.
  • Experience driving strategic account business plans.
  • Strong key account management experience in complex academic and community accounts, including identifying influential stakeholders and working with them to better serve patients.
  • A demonstrated record of business acumen, problem solving, effective prioritization, account management, and sales data analytics.
  • Experience fostering teamwork and collaboration in cross-functional account management.
  • A proactive, self-motivated approach to driving sales growth.
  • Experience with gastrointestinal, HER2, biomarker-driven therapeutics, and/or lung cancer.
  • Knowledge of key accounts and market dynamics.

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.21 billion; Jazz raised full-year guidance to $4.68 billion.
  • Actio's ABS-1230 adds first-in-class KCNT1 epilepsy upside after the September 15, 2026 close.
  • Oncology revenue exceeded $1 billion in 2025, driven by Zepzelca and Ziihera.

What critics are saying

  • Xywav faces Lupin, Teva, and Tris patent fights; generic entry threatens 2027 cash flow.
  • Xywav and EPIDIOLEX still dominate value; one patent loss or safety issue would crush earnings.
  • Jazz paid $820 million for Actio before registrational proof; ABS-1230 can still fail.

What makes Jazz Pharmaceuticals unique

  • Ziihera launched August 2026, targeting $3B-$5B across HER2-positive tumors.
  • EPIDIOLEX holds exclusivity into the late 2030s and now funds four new trials.
  • Xywav's low-sodium oxybate formulation keeps narcolepsy patients despite generic Xyrem pressure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Paid Vacation

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 16th, 2026
Jazz wins FDA approval for Ziihera as commercial chief Pearce plans to retire; 2026 guidance $4.6B+

Jazz Pharmaceuticals has won US Food and Drug Administration (FDA) approval for its cancer drug Ziihera. The approval raised the drug's projected peak sales range. Separately, chief commercial officer Samantha Pearce plans to retire by June 30, 2027, or when a successor is appointed. Jazz has started an internal and external search. In its second-quarter 2026 update, Jazz reported revenue of $1,208.3 million and raised full-year 2026 guidance to $4.60–4.75 billion. The share price still fell 7.6% after earnings. Simply Wall St's narrative projects revenue of $5.7 billion and earnings of $1.7 billion by 2029, implying a fair value of $294.27 a share.

Yahoo Finance
Sep 20th, 2026
Jazz Pharma raises zanidatamab peak sales target to $3B-$5B as oncology revenue hits $1B

Jazz Pharmaceuticals reported its oncology revenue surpassed $1 billion in 2025, marking a 32% year-over-year increase. The growth follows three recent product launches, including zanidatamab, Modeyso and Zepzelca's FORTE regimen. The company raised zanidatamab's estimated peak-sales opportunity to $3 billion-$5 billion. Jazz aims to increase HER2-directed treatment adoption in gastroesophageal cancer, where only 60% of eligible HER2-positive patients currently receive such therapy. Jazz estimates the US incidence of HER2-positive gastroesophageal adenocarcinoma at approximately 8,000 patients, with a labelled population of 3,000 to 4,000 patients. The company is also developing zanidatamab for biliary tract cancer, colorectal cancer, non-small cell lung cancer and breast cancer. Jazz maintains commercial investment whilst preserving financial flexibility for acquisitions across oncology, epilepsy and sleep disorders.

Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.